Nathan Bahary
AHN Cancer Institute-Med Onc & Infusions at Allegheny General Hospital
Office
(412) 325-5700
Fax (412) 442-2570 314 East North Avenue, Level One Pittsburgh, PA 15212Call today!
About
Nathan Bahary
Nathan Bahary MD, PhD received his B.A. from Cornell University, an M.D. from the Cornell University School of Medicine, and his Ph.D. from the Rockefeller University. He completed his residency at Beth Israel Hospital in Boston. He did his postgraduate training at the Dana Farber Cancer Institute, Harvard, and Brigham and Women’s Hospital system before joining the faculty of UPMC as the Director of the Pancreatic Cancer Center. Since 2021, he is the Division Chief of Medical Oncology at AHN Cancer Institute and Director of AHNCI Clnical Research. Amongst his various appointments Dr. Bahary is a member of the NCI Pancreatic Task Force, the Eastern Cooperative Oncology Group (ECOG) where he serves on the ECOG GI Steering Committee and the American Society of Clinical Oncology (ASCO) His basic research interests lie in the intersection between gastrointestinal development, metabolic stress pathways, immunology, and cancer. He has a broad research background in cancer genetics, developmental biology, molecular biology, and clinical investigations, with specific training and expertise in key research areas broadly within the field of gastrointestinal oncology, and specifically within pancreatic cancer. Building on his work at Harvard Medical School, Dr. Bahary is using insights gained by studying vertebrate development to determine how cancers grow. Clinical trials emanating from this research will continue at AHN Cancer Institute and are expected to lead to the development of new targeted agents and immunologic strategies for treating cancer.
Primary Specialty
Oncologist
Practice
AHN Cancer Institute-Med Onc & Infusions at Allegheny General Hospital
Gender
Male
Education
Weill Cornell Medical College
Training
DanaFarber Cancer Institute, Beth Israel Medical Center, Beth Israel Medical Center
Certification
American Board of Internal Medicine-Medical Oncology
Not Accepting New Patients
Degrees
Medical Doctor, Doctor of Philosophy
Admitting Hospitals
Allegheny General Hospital, West Penn Hospital
Office Name
AHN Cancer Institute-Med Onc & Infusions at Allegheny General Hospital
Languages
English
Business Hours
Monday:8:00 AM - 4:00 PM
Tuesday:8:00 AM - 4:00 PM
Wednesday:8:00 AM - 4:00 PM
Thursday:8:00 AM - 4:00 PM
Friday:8:00 AM - 4:00 PM
Saturday:Closed
Sunday:Closed
Services
clear cell renal cancer, chemotherapy iv infusion, multi-cancer early detection blood test, relapsed myeloma, testicular tumor, adjuvant chemotherapy, solid tumors, advanced malignancies, systemic therapy, mediastinal lymphadenopathy, gleason score, intravesical chemotherapy, hereditary kidney cancer, hormone receptor negative breast cancer, colorectal metastases, ductal carcinoma in situ (dcis), lobular carcinoma in situ (lcis), personal history of cancer, intestinal cancer, secondary cancer screening, long term side effects of cancer treatment, personal history of radiation therapy, personal history of chemotherapy, blood cancer chemotherapy, hyperthermic intraperitoneal chemotherapy (hipec), gynecologic cancer, blood transfusion therapy, prostate cancer chemotherapy, bladder cancer chemotherapy, testicular cancer chemotherapy, non steroidal aromatase inhibitors, hormone based chemotherapy, adolescent and young adult cancer (aya), metastatic rib cancer, breast cancer immunotherapy, relapsed hodgkin lymphoma, lymphoproliferative disorder, intravesical therapy, hormone receptor positive breast cancer, her2 positive breast cancer, carcinoma of unknown primary, targeted molecular therapy, cancer related anxiety disorder, cancer related depression, cancer related bereavement disorder, cancer related stress disorder, intrathecal chemotherapy, maintenance chemotherapy, consolidation chemotherapy, induction chemotherapy, er negative breast cancer, urachal tumor, malignant brain neoplasm, clinical trials, squamous cell carcinoma of the head and neck, aids related malignancies, intraarterial chemotherapy of tumors, cervical and endometrial cancers, genitourinary cancers, inflammatory breast cancer, recurrent breast cancer, occupational cancer, brain metastases, ear and temporal bone cancer, liver metastases, malignant carcinoid tumor of colon, ear canal cancer, hodgkin lymphoma, triple negative breast cancer, breast cancer therapy, breast cancer counseling, cancer immunotherapy, prostate cancer, adenocarcinoma of lung, acute lymphoblastic leukemia (all), abdominal chemotherapy, abdominal cancer, breast cancer, papillary cancer of thyroid, medullary cancer of thyroid, follicular cancer of thyroid, parotid cancer, squamous cancer of the lung, esophageal cancer, tracheal cancer, oral complications of cancer, non hodgkin lymphoma, myeloproliferative diseases, lymphedema therapy, hematologic malignancies, head and neck cancer, cancer related fatigue, hereditary cancer risk, ovarian cancer, head and neck tumors, reduced intensity conditioning regimens, bladder cancer, thyroid cancer, stomach cancer
Consumer Feedback
Add a Review
There are no recent reviews. Be the first!